Table 4.

New-onset diabetes in relation to quartiles of baseline copeptin.

Dependent variable		OR^* (95% CI) Q2_copeptin vs Q1_copeptin	OR^* (95% CI) Q3_copeptin vs Q1_copeptin	OR^* (95% CI) Q4_copeptin vs Q1_copeptin	P (test for linear trend)
Incident diabetes among non-DM^†	Crude	1.28 (0.76–2.15)	1.94 (1.19–3.14)	2.64 (1.66–4.19)	<0.001
Incident diabetes among non-DM^†	adjusted^§	1.37 (0.78–2.39)	1.79 (1.06–3.05)	2.09 (1.23–3.56)	0.004
Incident diabetes among non-IFG^‡	Crude	1.85 (0.81–4.20)	2.12 (0.95–4.73)	4.56 (2.18–9.52)	<0.001
Incident diabetes among non-IFG^‡	adjusted^§	1.80 (0.78–4.16)	1.92 (0.84–4.38)	3.48 (1.58–7.65)	0.001

Odds Ratio.

^†

Subjects who developed diabetes during follow-up (n=174) among subjects without diabetes at baseline (n=4377).

^‡

Subjects who developed diabetes during follow-up (n=79) among subjects without impaired fasting glucose at baseline (n=3702).

^§

Adjusted for age, sex, HDL, triglycerides, blood pressure, antihypertensive treatment, body mass index, waist, waist/hip ratio, cystatin C, CRP and prevalent cardiovascular disease, smoking, family history of diabetes, LDL, FBG and fasting insulin.